Rosemary Kraemer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rosemary Kraemer has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Autieri M
1 shared publicationBarbara Hempstead
From the Department of Pathology (R.K., P.J.B., Y.Y., J.J.H., R.U., R.D.), Division of Vascular Surgery (K.C.K.), and Division of Hematology (R.T., B.H.), Department of Medicine, Weill Medical College of Cornell University; The Rogosin Institute, Rockefeller University (Y.C., D.M.L.); and Beth Israel Medical Center (M.S.), New York, NY
1 shared publicationBerk B
1 shared publicationBourne A
1 shared publicationDaniel M. Levine
From the Department of Pathology (R.K., P.J.B., Y.Y., J.J.H., R.U., R.D.), Division of Vascular Surgery (K.C.K.), and Division of Hematology (R.T., B.H.), Department of Medicine, Weill Medical College of Cornell University; The Rogosin Institute, Rockefeller University (Y.C., D.M.L.); and Beth Israel Medical Center (M.S.), New York, NY
1 shared publicationDeMarco V
1 shared publication
Latest Publications
- 6 December 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (23) , 3644-3653
Decreased Neurotrophin TrkB Receptor Expression Reduces Lesion Size in the Apolipoprotein E–Null Mutant Mouse
Background— Accumulation of macrophages and smooth muscle cells in the vascular wall is critical for the development of atherosclerotic lesions. Although much is known about the factors that regulate macrophage recruitment to the vascular wall, the ability of growth factors to regulate smooth muscle cell recruitment in lesion development in vivo is unclear. Our previous studies demonstrated that neurotrophins and their receptors, the Trk receptor tyrosine kinases, are potent chemotactic factors for smooth muscle cells, and the expression of brain-derived neurotrophic factor (BDNF) and its cognate receptor, TrkB, is upregulated in human atherosclerotic lesions. Methods and Results— TrkB +/− mice on a 129/B6 background were backcrossed to apolipoprotein E (ApoE)–null ( ApoE −/− ) mice on the C57Bl/6 background for 6 to 8 generations. Immunohistochemical analysis demonstrated BDNF immunoreactivity in areas of macrophage and smooth muscle cell infiltration, whereas TrkB immunoreactivity was predominant in areas of neointimal smooth muscle cells. Moreover, haplodeficient expression of TrkB in ApoE −/− mice was associated with a 30% to 40% reduction in lesion size compared with ApoE −/− mice with normal expression of TrkB and a 45% decrease in smooth muscle cell accumulation in the lesions. Finally, reconstitution with bone marrow from ApoE −/− mice with normal TrkB expression did not restore lesion development in TrKB +/− / ApoE −/− mice. Conclusions— These results suggest that TrkB expression on smooth muscle cells contributes to lesion development in the cholesterol-fed ApoE–null mutant mouse. These data demonstrate, for the first time, a role for the neurotrophin TrkB receptor in atherosclerotic lesion development.
- 6 December 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (23) , 3644-3653
Decreased Neurotrophin TrkB Receptor Expression Reduces Lesion Size in the Apolipoprotein E–Null Mutant Mouse
Background— Accumulation of macrophages and smooth muscle cells in the vascular wall is critical for the development of atherosclerotic lesions. Although much is known about the factors that regulate macrophage recruitment to the vascular wall, the ability of growth factors to regulate smooth muscle cell recruitment in lesion development in vivo is unclear. Our previous studies demonstrated that neurotrophins and their receptors, the Trk receptor tyrosine kinases, are potent chemotactic factors for smooth muscle cells, and the expression of brain-derived neurotrophic factor (BDNF) and its cognate receptor, TrkB, is upregulated in human atherosclerotic lesions. Methods and Results— TrkB +/− mice on a 129/B6 background were backcrossed to apolipoprotein E (ApoE)–null ( ApoE −/− ) mice on the C57Bl/6 background for 6 to 8 generations. Immunohistochemical analysis demonstrated BDNF immunoreactivity in areas of macrophage and smooth muscle cell infiltration, whereas TrkB immunoreactivity was predominant in areas of neointimal smooth muscle cells. Moreover, haplodeficient expression of TrkB in ApoE −/− mice was associated with a 30% to 40% reduction in lesion size compared with ApoE −/− mice with normal expression of TrkB and a 45% decrease in smooth muscle cell accumulation in the lesions. Finally, reconstitution with bone marrow from ApoE −/− mice with normal TrkB expression did not restore lesion development in TrKB +/− / ApoE −/− mice. Conclusions— These results suggest that TrkB expression on smooth muscle cells contributes to lesion development in the cholesterol-fed ApoE–null mutant mouse. These data demonstrate, for the first time, a role for the neurotrophin TrkB receptor in atherosclerotic lesion development.
- 20 September 2002
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 91 (6) , 494-500
Reduced Apoptosis and Increased Lesion Development in the Flow-Restricted Carotid Artery of p75 NTR -Null Mutant Mice
Apoptosis of neointimal smooth muscle cells is a well-recognized component of the pathogenesis of vascular lesions. In recent studies, we have identified the neurotrophin receptor, p75NTR, as a mediator of apoptosis of neointimal smooth muscle cells. Neurotrophin ligands and p75NTR are selectively expressed in areas of atherosclerotic lesions with increased smooth muscle cell apoptosis and the neurotrophins are potent apoptotic agents for p75NTR-expressing smooth muscle cells in vitro. In the present study, we directly assess the role of p75NTR in lesion development in the flow-restricted carotid artery, a model of murine vascular injury. Ligation of the left carotid artery resulted in a 3- to 4-fold increase in lesion development in p75NTR-null mutant mice as compared with wild-type mice. The increase in lesion size was associated with a 70% decrease in apoptosis of neointimal smooth muscle cells, as assessed by in situ TUNEL analysis. These data suggest that under conditions of flow restriction, p75NTR activation impairs lesion formation by promoting smooth muscle cell apoptosis. These results further implicate p75NTR as an important regulator of smooth muscle cell apoptosis and lesion development after vascular injury.
- 20 September 2002
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 91 (6) , 494-500
Reduced Apoptosis and Increased Lesion Development in the Flow-Restricted Carotid Artery of p75 NTR -Null Mutant Mice
Apoptosis of neointimal smooth muscle cells is a well-recognized component of the pathogenesis of vascular lesions. In recent studies, we have identified the neurotrophin receptor, p75NTR, as a mediator of apoptosis of neointimal smooth muscle cells. Neurotrophin ligands and p75NTR are selectively expressed in areas of atherosclerotic lesions with increased smooth muscle cell apoptosis and the neurotrophins are potent apoptotic agents for p75NTR-expressing smooth muscle cells in vitro. In the present study, we directly assess the role of p75NTR in lesion development in the flow-restricted carotid artery, a model of murine vascular injury. Ligation of the left carotid artery resulted in a 3- to 4-fold increase in lesion development in p75NTR-null mutant mice as compared with wild-type mice. The increase in lesion size was associated with a 70% decrease in apoptosis of neointimal smooth muscle cells, as assessed by in situ TUNEL analysis. These data suggest that under conditions of flow restriction, p75NTR activation impairs lesion formation by promoting smooth muscle cell apoptosis. These results further implicate p75NTR as an important regulator of smooth muscle cell apoptosis and lesion development after vascular injury.